Furthermore, we analyzed the prognostic value of GJB2 in pan-cancers and the association of GJB2 with the clinical pathological stages, immune checkpoint (ICP) genes, tumor mutation burden (TMB), microsatellite instability (MSI), and neoantigens. This evidence concerns the gene GJB2 and neoplasm.